A Patient-centric Look at Gene Patents
One of the central policy issues injected into the current case of AMP v. Myriad Genetics is whether the BRCA patents are good for innovation and ultimately for patients. No matter how many times these allegations are repeated, all available evidence shows concerns over research and innovation to be unfounded.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063